U.S. FDA Grants Orphan Drug Designation to Riliprubart for Treating Antibody-Mediated Rejection in Solid Organ Transplant Recipients

Sanofi’s Riliprubart Receives U.S. FDA Orphan Drug Designation for Antibody-Mediated Rejection in Solid Organ Transplantation The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to riliprubart,…

Read MoreU.S. FDA Grants Orphan Drug Designation to Riliprubart for Treating Antibody-Mediated Rejection in Solid Organ Transplant Recipients

Regeneron Launches Innovative Donation Matching Initiative in Partnership with Independent Patient Assistance Charity

Regeneron Unveils Groundbreaking $200 Million Donation Matching Program to Expand Patient Access to Vision-Saving Treatments Regeneron Pharmaceuticals, a leader in biotechnology and a longtime advocate for equitable healthcare access, has…

Read MoreRegeneron Launches Innovative Donation Matching Initiative in Partnership with Independent Patient Assistance Charity